Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
Open Access
- 1 January 2021
- journal article
- research article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 53 (3), 226-228
- https://doi.org/10.4103/ijp.ijp_615_20
Abstract
, IFN-γ plays a key role in both primary and secondary cytokine storms. If the cytokine storm is not treated urgently, it will be fatal; therefore, it should be treated immediately. Anakinra, an interleukin-1 (IL-1) antagonist, tocilizumab, an IL-6 antagonist, and Janus kinase (JAK) inhibitors are successfully used in cytokine storm caused by COVID-19. However, sometimes, despite these treatments, the patient's clinical course does not improve. Emapalumab (Eb) is the human immunoglobulin G1 monoclonal antibody and is a potent and noncompetitive antagonist of IFN-γ. Eb can be life saving for cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and JAK inhibitors....Keywords
This publication has 17 references indexed in Scilit:
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 functionThe Journal of Experimental Medicine, 2019
- Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosisBlood, 2019
- Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantationHaematologica, 2019
- Emapalumab: First Global ApprovalDrugs, 2019
- Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infectionsBlood Advances, 2019
- Antibodies to watch in 2019mAbs, 2018
- Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine EraJoint Bone Spine, 2017
- An interferon‐γ‐related cytokine storm in SARS patientsJournal of Medical Virology, 2004